B7-H4 Expression as a Predictive Biomarker in Human Cervical Cancer Immunotherapy

Over the years Immunotherapy has evolved as a beneficial method in the treatment of cancer through the blockade of immune checkpoint molecules which are up regulated on activated lymphocytes, antigen presenting cells (APC`s) and on tumor cells to down regulate immune cell effector functions. B7-H4, which has been shown to be expressed on cervical cancer, is also associated with the poor prognosis of cervical cancer patients. Blockade of this ligand expressed on cervical cancers can be a novel target for molecular targeted immunotherapy against cervical cancer, which is known as the second most diagnosed malignancy among female worldwide.